Paxlovid is safe, effective and doesn’t cause ‘rebound,’ FDA says

Summary by Ground News

Pfizer’s antiviral COVID-19 treatment Paxlovid is safe and effective at treating adults with mild to moderate COVID-19 who are at high risk of progressing to severe disease, including hospitalization or death, according to a Food and Drug Administration (FDA) staff report.

Published 3 months ago · Washington, United States

News Articles

More
Filters

All

Left

Center

Right

Reuters

Pfizer's COVID drug data supports use in high-risk patients - FDA staff (March 14)

The U.S. health regulator's staff reviewers said on Tuesday data from Pfizer Inc's COVID-19 drug trials support its use in adults at high risk of progressing to severe disease, bringing the pill closer to a full approval.

3 months ago·United Kingdom

Read Full Article

abc News

No clear association between Paxlovid and COVID-19 rebound, FDA says

An FDA analysis did not find a clear association between the COVID-19 antiviral drug Paxlovid and illness rebound, the FDA said in a new report.

3 months ago·United States

Read Full Article

Hindustan Times

US FDA authorizes Pfizer Covid vaccine booster shots for children under 5

Pfizer Inc said on Tuesday that the U.S. Food and Drug Administration had expanded the emergency use authorization (EUA) of the company and its partner BioNTech SE's bivalent COVID-19 vaccine as a single booster dose in certain children.

3 months ago·New Delhi, India

Read Full Article

CNN

FDA advisers vote in support of Paxlovid approval for Covid-19 treatment in high-risk adults

Advisers to the US Food and Drug Administration voted 16-1 on Thursday in support of approval of Paxlovid, stating that the benefits outweigh the risks of the drug for treatment of mild-to-moderate Covid-19 in adult high risk for progression to severe disease, including hospitalization and death.

3 months ago·Atlanta, United States

Read Full Article

CNBC

FDA Staff Report Says Data Shows Pfizer's Covid Treatment Paxlovid Is Effective in High-Risk Adults

FDA staff said Pfizer’s clinical trial results on its Covid antiviral pill Paxlovid support its use in adults at high risk of progressing to severe disease.

3 months ago·United States

Read Full Article

KIFI

Paxlovid not linked to Covid-19 rebound, FDA says ahead of meeting to consider drug's full approval

By Janelle Chavez, CNN As the US Food and Drug Administration’s independent advisers prepare to discuss Thursday the full approval of Pfizer’s Covid-19 antiviral, Paxlovid, agency experts said this week that clinical trial data shows that it is safe and effective for treatment of mild to moderate illness in high-risk adults. The agency also concluded that Paxlovid is not associated with Covid-19 rebound, in which people test positive or see thei…

3 months ago·Idaho Falls, United States

Read Full Article